Abstract
Synbiotics have a positive effect on the composition of the gut microbiota. They will increase the production of short-chain fatty acid that has modulating effect on gastrointestinal epithelial cell integrity, appetite regulation, and immune function. The aim of this study is to determine the effect of synbiotics (L. plantarum Dad-13 and fructo-oligosaccharide) on gut microbiota composition (L. plantarum, Bifidobacterium and Enterobacteriaceae) in stunting children under five in Yogyakarta, Indonesia. The research methods used double blind randomized controlled trials with parallel design. The sample consisted of 39 stunting children under five which was divided into 19 subjects as a synbiotic group given synbiotic (L. plantarum Dad-13 1x10^{10} CFU and fructo-oligosaccharide 700 mg) powder and 20 subjects as a placebo group given skim milk. The intervention was carried out for 90 days. The result showed that, statistically, there were
significant differences in synbiotic group on gut microbiota (increased in L. plantarum and Bifidobacterium, while decreased in Enterobacteriaceae). Protein and carbohydrate were significantly increasing (p=0.000; p=0.001) in synbiotic group compared to placebo group. Body weight and height were significantly different (p=0.000) in both groups. Body weight and height of children on synbiotic group was increasing 1.02 and 1.6 times higher than placebo group. Neither morbidity nor weight loss was recorded throughout consumption period. Synbiotic powder has significantly positive effect on gut microbiota that can induce nutrient intake, height and weight gain of stunting children.

Introduction

Stunting is a form of chronic undernutrition which is height-for-age z-score below -2 standard deviations according to WHO Child Growth Standards median. That occurs during critical periods of growth and development in early life. One of the main causes of stunting is a lack of nutrients intake. Children with poor nutrient intake have a higher risk of becoming stunted. Nowadays, the concept of stunting has changed rapidly and has no longer been related to lack of nutrient intake, but it is related to the presence of gut microbiota like Lactobacillus and Bifidobacterium which can play a positive role in enhance nutrient absorption. Based on previous research, it shows that there is an infectious disease that causes inflammation of the small intestine, namely Pediatric Environmental Enteropathy (PEE). PEE causes dysbiosis/imbalance in gut microbiota which is thought to be the main cause of stunting in a group of children. A recent study in Bangladesh proved that infection with enteric bacteria, particularly Shigella and E. coli is associated with PEE in early life. In stunted children, inflammatory genus such as Enterobacteriaceae is found which is also found in many inflammatory bowel disease patients. Whereas, healthy children had more probiotic species such as Lactobacillus and Bifidobacterium.

Prevention of stunting is usually focused on improving nutrient, especially micronutrient intake. Based on previous study, it was reported that micronutrient intervention cannot prevent stunting. It is unfortunate that the prevalence of stunting cannot be reduced significantly using this method, especially in Indonesia. The 2018 Indonesian Basic Health Survey reported that around 30.8% of children under five years are stunted because of the lack of nutrition and infectious disease. Whereas in Yogyakarta, the percentage of stunting children under five years was 21.4% (15.1% stunted; 6.3% severely stunted), higher than the percentage of underweight that around 13% also due to the reasons of lack of nutrition and infectious diseases.

Synbiotics are a combination of probiotics and prebiotics that work together to provide beneficial effects such as nourish the gut microbiota and increase nutrient absorption. L. plantarum Dad-13 is an indigenous probiotic from Indonesia which is well developed for its utilization, the highest antimicrobial compared to other indigenous probiotics such as Mut 7, Mut 13, T3, SNP 2 and against such pathogenic bacteria as A. hydrophilla dky-5, S. dysentriae dky-4, S. typhi dky-3, E. coli OK, E. coli ST. Prebiotics are not only used to increase Bifidobacterium but are also shown to have an effect on improving physiological health. An example of physiological effects due to prebiotic consumption is that it can help the absorption of nutrients such as calcium, magnesium, trace elements and protein. Fructooligosaccharide (FOS) is a prebiotic that naturally presents in carbohydrates that cannot be digested by humans gut. This FOS also supports the growth of Bifidobacterium. The role of synbiotics in the balance of gut microbiota, which is mechanically able to increase the number of beneficial bacteria such as Bifidobacterium and Lactobacillus. Increased levels of anaerobic bacteria induce production of short-chain fatty acids (SCFA) such as butyrate, propionate and acetate acid. SCFA is produced from the microbiota gut fermentation process in the large intestine. This fermentation will induce changes in metabolic
environment on gastrointestinal lumen. These effects can lower pH in colon environment which can prevent the growth of pathogenic bacteria or pH sensitive bacteria such as Enterobacteriaceae and Clostridia, thereby nourishing the gut and increasing nutrient absorption, 22,23,24. Healthy intestinal is very important because the intestine contributes to overall health, such as ensuring optimal digestion and absorption of micro and macro nutrients, thereby increasing body weight and height in stunted children.

Therefore, synbiotics are considered as an effective way to treat stunting in early life. Supplementation with synbiotics powder can increase the richness of gut microbiota. The gut microbiota plays an important role in the absorption of nutrients and accelerates the improvement of nutritional status to support growth and development on stunting children. Thus, this study aimed to determine the effect of Lactobacillus plantarum Dad-13 and FOS on gut microbiota (L. plantarum, Bifidobacterium and Enterobacteriaceae) on stunting children.

Materials and Methods
Subject and Study Design
This study was a randomized, double-blind, placebo-controlled trial; 39 subjects were divided into an intervention (synbiotic group) and a control (placebo group) with 19 subjects in synbiotic group and 20 subjects in placebo group. This study used simple randomization, performed with computer-generated random numbers. It was conducted between January to May 2020 at Therapeutic Feeding Centre in Yogyakarta, Indonesia. The sample size was calculated using hypothesis testing for differences in 2 proportion between 2 independence groups. The minimal number of subjects required, with 95% confidence interval, power of 80% and 10% drop out into account. The inclusion criteria of the subject covered having height for age < -2SD, ranged between 12 - 59 months old, and did not take any probiotics in minimum month before the study took place or wash-in period. Figure 1 is a flow diagram showing the subject’s progression during this study period.

Study Procedures
Total period of this study was 90 days. During the study period, the synbiotic group was given 1 g of synbiotic powder, while the placebo group was given 1 g of skim milk without synbiotic each day. Each participant’s representative was asked to fill compliance form to ensure the product was consumed daily. The study product was a symbiotic powder containing L. plantarum Dad 13 1x10^{10} CFU and FOS 700 mg. L. plantarum Dad-13, indigenous
probiotic strain was deposited in ampoules at the Food and Nutrition Culture Collection (FNCC), Center for Food and Nutrition Studies, Universitas Gadjah Mada. The FOS was obtained from PT. Beneo GmbH.

**Fecal Sample Collection**
The fecal sample was collected before and after consumption period or day 0 and day 90. Respondents were given a fecal kit box as a place to store fecal sample a day before fecal collection. The fecal kit box consists of fecal bottle, trail paper, rubber gloves, masks and ice gel. Ice gel contained in the stool kit box was previously frozen before being used. The ice gel serves to keep the fecal samples' temperature cold. After the fecal collected, each sample was put into a sterile tube and mixed with 2 ml RNA-Later (Sigma-Aldrich; R0901; Saint Louis, MO, USA) than it was kept at freeze temperature (-180°C until -30°C) immediately before it was used.

**Fecal Microbiota Populations with Quantitative PCR (qPCR) Dna Extractions Protocol for Fecal Sample**
DNA extraction was extracted from stool samples by using the bead-beating method. Immediately, RNA-later was diluted 10 fold (w/v) and washed with 1 ml of Phosphate-buffered saline (PBS), feces samples were mixed with 300 µL of Tris-Sodium dodecyl sulfate (SDS) solution and 500 µL of TE saturated phenol breaking the cell bead beater (Fast Prep - 24TM, MP Biomedicals, USA) at a speed of 4000 rpm for 60 seconds. The supernatant obtained was added with 400 µL of phenol/chloroform/isoamyl alcohol (25:24:1; v/v) (Sigma-Aldrich; P2069; Saint Louis, MO, USA) than bead beater (Fast Prep -24TM, MP Biomedials, USA) for 30 seconds, followed by centrifugation at 13,000 rpm for 5 minutes at 4°C. After centrifugation, 250 µL of the supernatant was mixed with 25 µL of 3 M sodium acetate (pH 5.2) (Sigma-Aldrich; 567422; Saint Louis, MO, USA) and incubated for 30 minutes on ice. Three hundred microliters of isopropanol were added and centrifuged at 13,000 rpm for 5 minutes at 4°C. The DNA pellets were washed with 500 µL of cold ethanol 70% and shaken by hand and centrifuged at 13,000 rpm for 5 minutes at 4°C. Removing the supernatant was by decantation than drying the pellets in the tube at room temperature for approximately one night. The last step was adding 20 µl Tris-EDTA (TE) buffer pH 8 and dissolving the pellets and then, keeping them at 180°C to 300°C.

**Quantitative Real-Time PCR**
The microbiota analysis stage used the quantitative real time PCR method including DNA dilution from the results of DNA isolation, making PCR master mix, reading, making standard curves, and calculating the results of the total number of bacteria. DNA dilution was carried out to equalize the concentration of DNA included in the PCR master mix mixture. The concentration of bacterial DNA was made to 20 ng/µL for L. plantarum, Bifidobacterium and Enterobacteriaceae. The mastermix PCR was made every time you run PCR, consisted of a mixture of Eva Green (5 µL), forward primer (0.5 µL x 1000nM), reverse primer (0.5 µL x 1000nM), sample DNA (1 µL) and nuclease free water (3 µL). The real-time PCR tool used the Bio-Rad CFX-96. The results of multiplication and reading of bacterial DNA quantification were known using the analysis software Bio-Rad CFX Manager Software 3.0. The results of the analysis using the software showed the total L planta\textit{rum}, Bifidobacterium and Enterobacteriaceae bacteria in the sample. Primers used had a DNA base sequence as shown in table 1.

| Target            | Primer   | Sequence ( 5’ → 3’ )                  |
|-------------------|----------|---------------------------------------|
| Lactobacillus Plantarum\textsuperscript{28} | sg-Lpla-F | CTC TGG TAT TGA TTG GTG CTT GCA T     |
|                   | sg-Lpla-R | GTT CGC CAC TCA CTC AAA TGT AAA       |
| Bifidobacterium\textsuperscript{29}         | g-Bifid-F | CTC CTG GAA ACG GGT GG                |
|                   | g-Bifid-R | GGT GTT CTT CCC GAT ATC TAC A         |
| Enterobacteriaceae\textsuperscript{30}      | En-Isu-3F | TGC CGT AAC TTC GGG AGA AGG CA        |
|                   | En-Isu-3R | TCA AGG ACC AGT GTT CAG TGT C         |
Nutrient Intake
Nutrient intake was measured using semi quantitative food frequency questioner (SQFFQ) method. SQFFQ is a method to describe the individual nutrients intake habits at a certain as in use in time. This method is the same as the method of frequency of food both in format but modified by adding question about quantity or size of food. SQFFQ was carried out before and after consumption period by interviewed mother of the children at Therapeutic Feeding Centre. Nutrient intake was analyzed using Nutri Survey 2007 software based on subject’s SQFFQ Nutri Survey is English translation of a professional German nutrition software (EBISpro).

Anthropometric Measurement
Measurement of weight was taken to the nearest of 0.1 kg, using a standardized 20 kg infant digital scale while measurement of height was taken to nearest of 0.1 cm, using measuring board for child under 2 years and microtoise for child over 2 years. Body weight and height were measured every month during consumption period.

Data Analysis
Statistical analysis was performed in R program (v.4.0.3). A comparison between the group was analyzed using t-test. The data have a normal distribution based on Kolmogorov Smirnov analysis. Therefore, a comparison between the groups was analyzed using t-test and chi-square analysis. All analysis was performed on an intention to-treat basis where p-value< 0.05 was considered statistically significant.

Ethical Consideration
Parents or legal guardians were fully informed about the aim of the study, and they signed informed consent obtained from at least one parent or legal guardians because the subjects were minors. Protocol was approved by the Ethical Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia. (Approval date: 25 November 2019; Ref. number: KE/FK/1388/EC/2019) The study was conducted in accordance with Declaration of Helsinki.

Results
There was no significant difference on synbiotic and placebo group (p>0.05), so it could be concluded that the subjects had the same characteristics at the baseline. Characteristics of research subjects including age, sex, weight, and height of children under five is shown in Table 2.

| Characteristics | Synbiotic Group (n=19) | Placebo Group (n=20) | p   |
|-----------------|------------------------|----------------------|-----|
| Sex             | 12                     | 7                    | 0.905<sup>a</sup> |
| Male            | 13                     | 7                    |     |
| Female          |                        |                      |     |
| Age, month      | 26±8.34                | 29±5.78              | 0.194<sup>b</sup> |
| Weight, kg      | 8.5±0.94               | 9.0±0.82             | 0.103<sup>b</sup> |
| Height, cm      | 78.96±5.4              | 80.9±4.55            | 0.241<sup>b</sup> |

<sup>a</sup>Chi-Square test, <sup>b</sup>Independent t-test, significant if p-value<0.05, Values are expressed as mean± SD.

Effect Consumption of Synbiotics Powder on L. plantarum, Bifidobacterium and Enterobacteriaceae
The difference in population of L. plantarum, Bifidobacterium and Enterobacteriaceae was analyzed after consuming synbiotics powder for 90 days. There was a significant increase in the population of L. plantarum and Bifidobacterium and a significant decrease in the population of Enterobacteriaceae in the synbiotic group and not in the placebo group (Table 3).

Energy, carbohydrate, protein intake in placebo group did not significant change after intervention (p>0.05) whereas, carbohydrate and protein intake in synbiotic group significantly changed after 90 days intervention (p<0.05) (Table 4).
The mean of body weight gain in synbiotic group was 1.44±0.65 kg, from 8.53±0.92 to 9.97±1.34 kg while in placebo group was 0.78±0.62 kg, from 9.02±0.82 kg to 9.8±0.89 kg. Figure 2 shows the slope at synbiotic group was higher than placebo group, which was 0.083 and 0.081, consecutively. It showed that within 90 days of synbiotic consumption might be increase 0.083 kg of bodyweight every week and 0.081 kg in placebo group every week. Coefficient of determination ranges from 0 to 1 on both groups, it can be said that the effect of consuming sybiotic powder on body weight is large. This means that the model used is good to explain the effect of these variables. There was a significant difference in bodyweight after 90 days intervention on both groups (p-value<0.05) (table 5).

The mean of height in synbiotic group was 3.89±0.80 cm, from 78.95±5.56 to 80.92±4.66 cm while in placebo group was 0.85±0.74 cm, from 80.92±4.66 cm to 83.43±4.52 cm. Figure 3 shows the slope at synbiotic group was 0.3375, greater than placebo group 0.2107. It means that every week of symbiotic consumption could increase 0.3375 cm in synbiotic group, while the height in placebo group increased 0.2107 cm every week. Coefficient of determination ranges from 0 to 1 on both groups, it can be said that the effect of consuming synbiotic powder on body weight is large. This means that the model used is good to explain the effect of these variables. There was a significant difference in height after 90 days intervention on both groups (p-value<0.05) (table 5).
Fig. 2: Linear regression of weight in synbiotic and placebo group, $y_1$ represents synbiotic group and $y_2$ represents placebo group.

Fig. 3: Linear regression of height in synbiotic and placebo group, $y_1$ represents synbiotic group and $y_2$ represents placebo group.

Table 5: The difference of weight and height

| Group          | Before         | After          | p-value |
|----------------|----------------|----------------|---------|
| Weight (kg)    | Synbiotic group 8.53±0.97 | 9.96±1.41 | 0.000*  |
|                | Placebo group 9.02±0.84 | 9.80±0.91 | 0.000*  |
| Height (cm)    | Synbiotic group 78.95±5.56 | 83.08±5.56 | 0.000*  |
|                | Placebo group 80.92±4.66 | 83.43±4.51 | 0.000*  |

Data are presented as mean±SD *Independent sample t-test, a significantly different (p<0.05)

Table 6: Changes in Body Weight and Height

|                  | Synbiotic group (Mean±SD) | Placebo group (Mean±SD) |
|------------------|---------------------------|-------------------------|
|                  | Baseline  | Day 30  | Day 60  | Day 90  | Baseline | Day 30  | Day 60  | Day 90  |
| Weight (kg)      | 8.5±0.94 | 9.0±1.01 | 9.4±1.29 | 10.0±1.38 | 9.0±0.82 | 9.2±0.78 | 9.5±0.80 | 9.8±0.89 |
| Height (cm)      | 78.9±5.48 | 80.5±5.86 | 81.7±5.38 | 83.1±5.42 | 80.9±4.55 | 81.7±4.50 | 82.7±4.45 | 83.4±4.40 |
The consumption of syniotics for 90 days was able to increase body weight and height in stunted children. Changes in body weight and height before and after intervention shows growth rate has improved (Table 6).

**Discussion**

Based on real-time PCR analysis shown after 90 days intervention, the population of *L. plantarum* and *Bifidobacterium* increase significantly and a significant decrease in the *Enterobacteriaceae* population. The increase of *Bifidobacterium* population could be resulted from increase in *L. plantarum*. In addition, the benefits of FOS, among others are to increase Bifidobacteria, *Lactobacillus* and to reduce *Enterobacteriaceae* and Clostridium perfringen. The increase in *Bifidobacterium* in the colon can have a positive impact on health. *Bifidobacterium* found in the colon helps maintaining health and is a bacterium that is much more important for life. The decrease or loss of *Bifidobacterium* in the human colon indicates that we are not healthy. In line with previous study, giving a synbiotic containing *L. casei shirota* (3 x 10^10 CFU) and galacto-oligosaccharide (GOS) (2.5 g) for every 80 ml for 2 weeks can significantly increase *Bifidobacterium*. The increase in *Bifidobacterium* in the colon can have an impact positive for health. *Bifidobacterium* found in the colon helps in nourishing health and is a bacterium that is much more important to life. Decrease or loss of *Bifidobacterium* in the human colon is indicative that we are not well. Low number of *Bifidobacterium* presents in malnutrition and inflammatory bowel syndrome patients. Overall there is a trend towards low levels of *Bifidobacterium* with various disease, so it plays a role in health. *Lactobacillus* and *Bifidobacterium* (which can decrease inflammation, strengthen gut barrier function, inhibit pathogens, and mediate other beneficial effects under certain conditions), are deficient in stool on undernourished children.

Conversely, the decreasing population of *Enterobacteriaceae* can cause inflammation or pathogens bacteria that can cause PEE. The previous study revealed that overall microbiota of stunted children were enriched in inflammogenic bacteria belonging to the Proteobacteria phylum, whereas those of children who were not stunted were enriched in probiotic species such as *B. longum*. The previous studies stating that 30 out of 30 healthy adult subjects experienced an increase in the population of *L. plantarum* after consuming the probiotic *L. plantarum* Dad-13 for 20 days. Previous research also stated that 20 out of 20 healthy adolescent subjects experienced an increase in the amount of *L. plantarum* (mean increase of 6.14 log 10 CFU/g of feces) after consuming the probiotic *L. plantarum* Dad-13 for 2 months. This shows that *L. plantarum* Dad-13 is able to live in the human gastrointestinal tract and has a beneficial impact on health. In line with previous research which states that *L. plantarum* Dad-13 is a strain that can survive in the digestive system, is resistant to bile salt and gastric juice, and is found in human feces who consume it. Subjects who experienced a decrease were higher than the increase in the population of the *Enterobacteriaceae* after drinking *L. plantarum* Dad-13 probiotics for 2 months, and it occurred in healthy adolescents in Yogyakarta, namely 11 out of 20 subjects that experienced a decrease in *E. coli* and 15 and 20 subjects that experienced a decrease in Coliform non *E. coli*. The consumption of *L. plantarum* Dad-13 for 20 days can reduce the *Enterobacteriaceae* population in 19 of 30 subjects (the average decrease is 0.71 log10 CFU/g of feces). This shows that it can reduce *Enterobacteriaceae* in the feces of some subjects. Fecal microbial communities from both undernourished cohorts included increased proportions of pathogenic taxa within Proteobacteria, including *Enterobacteriaceae*, *Escherichia*, *Klebsiella*, and *Shigella*, as confirmed elsewhere. It should be noted that a similar pattern (increased proportions of Proteobacteria with decreased microbial diversity) is found in inflammatory bowel disease. On the other hand, genera containing potentially beneficial organisms are depleted in the undernourished gut.

Consumption 90 days of synbiotic powder significantly changes in nutrient intake especially protein and carbohydrate. In summary, synbiotic treatment for 90 days might have promotes protein and carbohydrate intake. The consumption of protein and carbohydrate is more than 70% RDA in Indonesia. Children in developing country typically consume plant-based diets rich in complex plant polysaccharides. In line with previous study, the consumption of gut microbiota in school-
age children in Yogyakarta Indonesia and Khon Kaen Thailand was dominated by Prevotella bacteria (P-type) because of dominant intake in resistant starches. Conversely, fat intake tends to increase higher than the synbiotic group. This result was in line with previous studies stating that increasing consumption of high fat potentially increases the population of Enterobacteriaceae (inflammogenic bacteria). Stunting is closely related to food intake that is not sufficient for nutritional needs. Deficiencies in the intake of macro nutrients, especially energy and protein, as well as micronutrients contribute to this. Treatment with synbiotic powder for 90 days can be expected to increase nutrient intake on stunting children. In previous study, probiotic and prebiotic could increase bacterial deconjugation of bile acids and affect food intake. Low level of serum leptin can result increase in appetite that can make changes in food intake.

In this study weight and height were significantly increasing after 90 days synbiotic treatment. Consumption of synbiotic (L. plantarum Dad-13 and FOS) group for 90 days may increase the bodyweight and height of children by 1.02 and 1.6 times higher than placebo group. It is line with the previous study stating that supplementation of E. faecium IS27526 at 108 cfu/day and 125 ml low fat milk for 90 days may increase the bodyweight of children by 1.5 times higher than supplementation of 125 ml low fat milk only. It might be due to the synergy between probiotics and prebiotics stimulate cell proliferation in order to expand the surface of mineral absorption thereby increasing mineral bioavailability so that facilitating better nutrient absorption, mostly of magnesium and calcium. Hence, the increasing on weight and height might be related to the role of synbiotic.

The main aim of prebiotics is to stimulate the growth and activity of beneficial bacteria in the gastrointestinal tract, which confers a health benefit on the host. Through mechanisms including antagonism (the production of antimicrobial substances) and competition for epithelial adhesion and nutrients, the intestinal microbiota acts as a barrier for pathogens. Final products of carbohydrate metabolism are mostly SCFAs, namely: acetic acid, butyric acid, and propionic acid, which are subsequently used by the host as a source of energy. As a result of the fermentation of carbohydrates, Bifidobacterium or Lactobacillus may produce some compounds inhibiting the development of gastrointestinal pathogens, as well as causing a reduction in the intestinal pH. Moreover, Bifidobacterium demonstrates tolerance to the produced SCFAs and reduced pH. Therefore, due to their favorable effect on the development of beneficial intestinal bacteria, the administration of prebiotics may participate in the inhibition of the development of pathogens. SCFAs are a subset of fatty acids that are produced by the gut microbiota during the fermentation of partially and non-digestible polysaccharides. Diet composition and intake (e.g., types of fibers and iron) have been reported to influence the microbiota composition and to impact gut moility and to strengthen the gut barrier functions. SCFAs are estimated to contribute 6%–10% of total energy requirements, and the contribution is expected to be higher for humans consuming high-fiber diets and for herbivorous species.

Efficient energy metabolism requires communication between the gut and peripheral organs such as the pancreas, liver, adipose tissue, and brain. Information about nutritional status in the gut is relayed by various signals, including gut derived hormones such as glucagon-like peptide-1 (GLP-1). Transient postprandial increases in GLP-1 have many effects on metabolism, including the stimulation of insulin secretion (incretin effect), inhibition of gastric emptying, and an increased feeling of satiety. Secretion of GLP-1 from enteroendocrine L cells can be stimulated by sugars, amino acids, and long-chain fatty acids. Dietary supplementation with fermentable fibers has been shown to increase GLP-1 levels in rodents and humans and SCFAs can stimulate GLP-1 secretion in vitro. Thus, it has been suggested that the gut microbiota increases GLP-1 levels through the production of SCFAs. The absence of SCFAs-producing microbes in GF colon results in significantly higher plasma GLP-1 levels. This colonic-derived GLP-1 has an important role in slowing small intestinal transit, which may be an adaptive response for promoting nutrient absorption. It can impact to increase in body weight and height. Synbiotic treatment for 90 days is able nourish gut microbiota than can give
a positive effect on nutrient intake and anthropometric parameters (weight and height) on stunting children.

**Conclusion**
Consumption synbiotic (L. plantarum Dad-13 and fructo-oligosaccharide) powder for 90 days was significant in gut microbiota composition (increasing on population of L. plantarum and Bifidobacterium; decreasing on population of Enterobacteriaceae). In addition, it is also significant in nutrient intake such as protein and carbohydrates. Synbiotic also may increase the bodyweight and height of children by 1.02 and 1.6 times higher than placebo group. Synbiotic powder has significantly positive effect on gut microbiota that can induce nutrient intake, height and weight gain of stunting children.

**Acknowledgements**
We are grateful to Food and Nutrition Culture Collection (FNCC), Center for Food and Nutrition Studies, Universitas Gadjah Mada for supplying L. plantarum Dad-13 for this study. We also thanks to Therapeutic Feeding Centre Yogyakarta where the study was carried out and last but not least thank the participating parents and their children who volunteered for the study.

**Funding**
This study was supported by Program Rekognisi Tugas Akhir (RTA) 2020 Universitas Gadjah Mada (732/UN1.P.III/KPT/HUKOR/2020).

**Conflict of Interest**
All authors report that there is no conflict of interest.

**References**

1. WHO. Reducing Stunting In Children.; 2018. https://apps.who.int/iris/bitstream/handle/10665/260202/9789241513647-eng.pdf?sequence=1
2. Dewey KG, Begum K. Long-term consequences of stunting in early life. *Matern Child Nutr* Published online 2011. doi:10.1111/j.1740-8709.2011.00349.x
3. Habimana S, Biracyaza E. Risk Factors Of Stunting Among Children Under 5 Years Of Age In The Eastern And Western Provinces Of Rwanda: Analysis Of Rwanda Demographic And Health Survey 2014/2015. *Pediatr Heal Med Ther.* 2019;Volume 10:115-130. doi:10.2147/phmt.s222198
4. Pekmez CT, Dragsted LO, Brahe LK. Gut microbiota alterations and dietary modulation in childhood malnutrition – The role of short chain fatty acids. *Clin Nutr.* 2019;38(2):615-630. doi:10.1016/j.clnu.2018.02.014
5. Vonaeisch P, Randremanana R, Gody JC, et al. Identifying the etiology and pathophysiology underlying stunting and environmental enteropathy: Study protocol of the AFRIBIOTA project. *BMC Pediatr.* 2018;18(1). doi:10.1186/s12887-018-1189-5
6. Monira S, Nakamura S, Gotoh K, et al. Gut microbiota of healthy and malnourished children in Bangladesh. *Front Microbiol.* 2011;2(NOV):1-7. doi:10.3389/fmicb.2011.00228
7. Gordon JI, Dewey KG, Mills DA, Medzhitov RM. The human gut microbiota and undernutrition. *Sci Transl Med.* 2012;4(137):2-7. doi:10.1126/scitranslmed.3004347
8. Penny ME dit. Micronutrients in the treatment of stunting and moderate malnutrition. *Nestle Nutr Inst Workshop Ser.* 2012;70:11-21. doi:10.1159/000337388
9. Semba RD, Trehan I, Gonzalez-Freire M, et al. Perspective: The Potential Role of Essential Amino Acids and the Mechanistic Target of Rapamycin Complex 1 (mTORC1) Pathway in the Pathogenesis of Child Stunting. *Adv Nutr.* 2016;7(5):853-865. doi:10.3945/an.116.013276
10. Goudet SM, Bogin BA, Madise NJ, Griffiths PL. Nutritional interventions for preventing stunting in children (Birth to 59 months) living in urban slums in low-and middle-income countries (LMIC). *Cochrane Database Syst Rev.* 2019;2019(6). doi:10.1002/14651858.CD011695.pub2
11. Hemalatha R, Ouwehand AC, Saarinen MT, Prasad U V., Swetha K, Bhaskar V. Effect of probiotic supplementation on total lactobacilli, bifidobacteria and short chain fatty acids in 2–5-year-old children. *Microb Ecol Health Dis.*
20. Hijova E, Chmelarova A. Short Chain Fatty Acids and Intestinal Microflora. 2006;(February):3-6.
21. Rios-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, De los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. *Front Microbiol.* 2016;7(FEB):1-9. doi:10.3389/fmicb.2016.00185
22. Den Besten G, Van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res.* 2013;54(9):2325-2340. doi:10.1194/jlr.R036012
23. Nagpal R, Wang S, Ahmadi S, et al. Human-origin probiotic cocktail increases short-chain fatty acid production via modulation of mice and human gut microbiome. *Sci Rep.* 2018;8(1):1-15. doi:10.1038/s41598-018-30114-4
24. Maghfirrotin Marta B, Tyas U, Muhammad Nur C, Jaka W, Endang Sutriswati R. Effects of Consumption of Probiotic Powder Containing *Lactobacillus Plantarum* Dad-13 on Fecal Bacterial Population in School-Age Children in Indonesia. *Int J Probiotics Prebiotics.* 2019;14(1):1-8. doi:10.37290/ijpp2641-7197.14:1-8
25. Nakayama J, Watanabe K, Jiang J, et al. Diversity in gut bacterial community of school-age children in Asia. *Sci Rep.* 2015;5:1-12. doi:10.1038/srep08397
26. Matsuda K, Tsuji H, Asahara T, Matsumoto K, Takada T, Nomoto K. Establishment of an analytical system for the human fecal microbiota, based on reverse transcription-quantitative PCR targeting of multicycle rRNA molecules. *Appl Environ Microbiol.* 2009;75(7):1961-1969. doi:10.1128/AEM.01843-08
in human feces. *Appl Environ Microbiol.* 2002;68(11):5445-5451. doi:10.1128/AEM.68.11.5445-5451.2002

30. Matsuda K, Tsuji H, Asahara T, Kado Y, Nomoto K. Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. *Appl Environ Microbiol.* 2007;73(1):32-39. doi:10.1128/AEM.01224-06

31. Tang Y, Liu Y, Xu L, et al. Validity and reproducibility of a revised semi-quantitative food frequency questionnaire (SQFFQ) for women of age-group 12-44 years in Chengdu. *J Heal Popul Nutr.* 2015;33(1):50-59. doi:10.3329/jhpn.v33i1.3194

32. Mitsuoka T. Establishment of intestinal bacteriology. *Biosci Microbiota, Food Heal.* 2014;33(3):99-116. doi:10.12938/bmfh.33.99

33. Matsumoto K, Takada T, Shimizu K, et al. The Effects of a Probiotic Milk Product Containing *Lactobacillus casei* Strain Shirota on the Defecation Frequency and the Intestinal Microflora of Sub-optimal Health State Volunteers: A Randomized Placebo-controlled Cross-over Study. *Biosci Microflora.* 2006;25(2):39-48. doi:10.12938/bifidus.25.39

34. Arboleya S, Watkins C, Stanton C, Ross RP. Gut bifidobacteria populations in human health and aging. *Front Microbiol.* 2016;7(AUG):1-9. doi:10.3389/fmicb.2016.01204

35. Taverniti V, Guglielmetti S. Methodological issues in the study of intestinal microbiota in irritable bowel syndrome. *World J Gastroenterol.* 2014;20(27):8821-8836. doi:10.3748/wjg.v20.i27.8821

36. Ghosh TS, Gupta S Sen, Bhattacharya T, et al. Gut microbiomes of Indian children of varying nutritional status. *PLoS One.* 2014;9(4):1-13. doi:10.1371/journal.pone.0095547

37. Dinh DM, Ramadass B, Kattula D, et al. Longitudinal analysis of the intestinal microbiota in persistently stunted young children in south India. *PLoS One.* Published online 2016. doi:10.1371/journal.pone.0155405

38. Dolly P, Anishaparvin A, Joseph GS, Anandharamakrishnan C. Microencapsulation of *Lactobacillus plantarum* (mtcc 5422) by spray-freeze-drying method and evaluation of survival in simulated gastrointestinal conditions. *J Microencapsul.* Published online 2011. doi:10.3109/02652048.2011.599435

39. Liwan SY, Utami T, Murdiati A, Triwono P, Rahayu ES. Dietary patterns and effect of consumption of probiotic powder containing indigenous bacteria *Lactobacillus plantarum* Dad-13 on Streptococcus, Enterococcus, Escherichia coli and Klebsiella pneumoniae in the gut of students at Junior High School Pangururan. *Int Food Res J.* 2020;27(5):790-797.

40. Nakayama J, Yamamoto A, Palermo-Conde LA, et al. Impact of westernized diet on gut microbiota in children on Leyte island.

41. Bardosono S, Dewi LE, Sukmaniah S, Permadhi i, EkaAD, Lestarina L. Effect of a six-month iron-zinc fortified milk supplementation on nutritional status, physical capacity and speed learning process in Indonesian underweight schoolchildren: Randomized, placebo-controlled. *Med J Indones.* 2009;18(3):193-202. doi:10.13181/mji.v18i3.361

42. Blaney S, Febuhartanty J, Sukotjo S. Feeding practices among Indonesian children above six months of age: A literature review on their potential determinants (part 2). *Asia Pac J Clin Nutr.* 2015;24(1):28-37. doi:10.6133/apjcn.2015.24.1.14

43. Hosseinifard E-S, Bavafa-Valenlia K, Saghafi-Asl M, Morshedi M. Antioxidative and Metabolic Effects of *Lactobacillus plantarum*, Inulin, and Their Symbiotic on the Hypothalamus and Serum of Healthy Rats. *Nutr Metab Insights.* 2020;13:117863882092509. doi:10.1177/1178638820925092

44. Suroso IS, Koestomo FP, Novitasari N, Zakaria FR, Yulianasari, Koesnandar. Novel probiotic Enterococcus faecium IS-27526 supplementation increased total salivary sIgA level and bodyweight of pre-school children: A pilot study. *Anaerobe.* 2011;17(6):496-500. doi:10.1016/j.anaerobe.2011.06.003

45. Parvaneh K, Jamaluddin R, Karimi G, Erfani R. Effect of probiotics supplementation on bone mineral content and bone mass density. *Sci World J.* Published online 2014. doi:10.1155/2014/595962
46. Kurniasari Y, Juffrie M, Jamil MD. Kadar kalsium serum pada anak stunting dan tidak stunting usia 24-59 bulan. *J Gizi Klin Indones.* 2016;12(3):108-115.

47. Whisner CM, Castillo LF. Prebiotics, Bone and Mineral Metabolism. *Calcif Tissue Int.* Published online 2018. doi:10.1007/s00223-017-0339-3

48. Grajek W, Olejnik A, Sip A. Probiotics, prebiotics and antioxidants as functional foods. *Acta Biochim Pol.* 2005;52(3):665-671. doi:10.18388/abp.2005_3428

49. Gibson GR, Wang X. Regulatory Effects of the Growth of Bifidobacteria on Other Large Intestinal Microorganisms. *J Appl Bacteriol.* 1994;77(4):412-420. https://doi.org/10.1111/j.1365-2672.1994.tb03443.x

50. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. *The Role of Short-Chain Fatty Acids in Health and Disease.* Vol 121. 1st ed. Elsevier Inc.; 2014. doi:10.1016/B978-0-12-800100-4.00003-9

51. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes.* 2016;7(3):189-200. doi:10.1080/19490976.2015.1134082

52. Yan J, Herzog JW, Tsang K, et al. Gut microbiota induce IGF-1 and promote bone formation and growth. *Proc Natl Acad Sci.* Published online 2016. doi:10.1073/pnas.1607235113